Marco Meglio

Over half of the patients (56.7%) discontinued at least one class of acute migraine medication within 12 months post-erenumab initiation.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on insomnia.

The phase 2 study, expected to include 575 patients with acute migraine, will use percentage of participants with freedom from pain and freedom from the most bothersome symptom as the coprimary end points.

Over a 12-month period, patients showed sustained improvements in disease progression through valbenazine, regardless of concomitant antipsychotic treatment.

Mind Moments®, a podcast from NeurologyLive®, brings you an exclusive interview with Daniel Ontaneda, MD, PhD. [LISTEN TIME: 27 minutes]

The KINETIC 2 study did not show statistically significant improvement in essential tremor symptoms compared to placebo, leading to the termination of its development for this condition.

This trial aims to explore the role of the noradrenergic system in behavioral and cognitive outcomes and could lead to new therapeutic strategies for managing PSP.

ION464 is designed to inhibit the production of the alpha-synuclein protein, aiming to reduce the accumulation of this protein in the brain, which is believed to be a key factor driving neurodegeneration in MSA and Parkinson disease.

The consultant neurologist and senior lecturer at St. Georges Hospital in London, provided commentary on the diagnosis, management, and future research around neuropsychiatric symptoms of Parkinson disease.

ELATE, a multicenter, randomized, double-blind, placebo-controlled trial, aims to address the limitations of current oral therapies by exploring a targeted, localized treatment option.

Kelly Brazzo, founder and CEO of CureLGMD2i Foundation, and Dennis Akkaya, chief Commercial Officer at MyTomorrows, share insight on a new partnership that aims to ease accessibility to drug development trials for patients with LGMD.

In a post hoc analysis of the COSMOS study, 24-hour LCIG infusion led to a reduction in nocturnal and morning akinesia, though many patients continued to rely on nighttime add-on medications.

While participants responded positively to nutritional guidance and the Mediterranean diet, they expressed negative views on the ketogenic diet due to its restrictive nature, social impracticality, and gastrointestinal side effects of MCT oil.

Patients reported increased good ON time and improved confidence in daily activities while experiencing a lower treatment burden compared to their previous medication regimens.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on cryptogenic stroke.

Lu AF84222 was considered well tolerated, with greater treatment effects observed in a subgroup of patients with less impaired multiple system atrophy.

Despite showing no differences vs placebo on the primary end point of gait parameters, TAK-071-treated patients demonstrated significant improvements in global cognition score.

Change from baseline in Myasthenia Gravis Activities of Daily Living score was statistically significant for inebilizumab-treated patients and the therapy showed a safe and well-tolerated profile without new safety signals.

Tim Miller, MD, director of functional neurosurgery at the Marcus Neuroscience Institute, Baptist Health, provided commentary on the use of HIFU as a non-invasive treatment for patients with essential tremor and specific types of Parkinson disease.

Results from the phase 3 TEMPO-2 trial, an additional study assessing tavapadon as a flexible-dose monotherapy, are expected by the end of this year.

A pair of neurologists from the University of California, Irvine, detailed some of the training and career focuses of large federal agencies in effort to address the shortage of neurologists. [WATCH TIME: 4 minutes]

RNS60 may lengthen survival by slowing FVC progression, particularly in participants with low NfL and MCP-1 levels at baseline, suggesting a potential target subgroup for future studies.

The company expects to complete the trial in Q1 2025 and anticipates it will use the feedback from regulators to guide an accelerated approval.

Recruitment for the OCTOPUS trial, which explores alpha-lipoic acid and metformin in progressive multiple sclerosis (MS), is progressing well with nearly half of participants in stage 1 already randomized.

Representatives from the SCN8A Alliance discussed ways to improve the quality of life for children with SCN8A-related epilepsy, highlighting the critical role of early genetic diagnosis and targeted interventions. [WATCH TIME: 4 minutes]

In the study, patients with spinocerebellar ataxia treated with troriluzole demonstrated statistically significant improvements at years 1 and 2 on the treatment.

Stewart Tepper, MD, Vice President at the New England Institute for Neurology and Headache in Stamford, Connecticut, provided commentary on a wide-scale analysis of nearly 5000 patients testing the effects of rimegepant.

In the ULTIMATE study subgroup, ublituximab consistently lowered disease activity in MS patients, suggesting the MSDA test may effectively assess therapeutic efficacy.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on myasthenia gravis.

In the original phase 3 studies, treatment with ozanimod resulted in significant reductions in clinical relapses and lesion counts on MRI as well as slowed brain volume loss relative to intramuscular interferon-β-1a.